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Clinical Trial
No Benefit for Folate Supplementation in Patients with CRF
Elevated homocysteine levels have been associated with increased risk of cardiovas-cular events; homocysteine can be lowered with folate supplementation. Patients
with chronic renal failure often have elevated homocysteine levels and are known to be
at increased risk for cardiac events, though no causal link between the two has been
proven.TheAtherosclerosis andFolicAcid SupplementationTrial (ASFAST) enrolled
approximately 300 patients with chronic renal failure (CRF) who were randomized to
either 15mg of folate daily or placebo and followed for over three years. There were no
significant differences in either clinical events or the rate of intima medial thickness
progression. This study suggests that there is no cardiovascular benefit to folate
supplementation in patients with CRF. See page 1108. See figure.
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Atherosclerosis
Atherosclerosis in HIV: Virus, HAART, or Metabolic Syndrome?
Several lines of evidence suggest that patients with human immunodeficiency virus(HIV) are at increased risk for cardiovascular events and/or have impaired endo-
thelial function.The etiology remains controversial and is likelymultifactorial. Putative
risk factors include inflammation associated with viremia, side effects of highly active
antiretroviral therapy (HAART), or a higher prevalence of traditional cardiac risk
factors. vanWijk and colleagues compared flow-mediated vasodilation (FMD), aortic
pulse wave velocity, and carotid intima-media thickness in patients with HIV who
fulfilled theNational Cholesterol Education Program criteria formetabolic syndrome,
and those who did not. They also studied two control groups without HIV, one with
diabetes and one group of healthy controls. FMD was similarly impaired in HIV-
infected patients without the metabolic syndrome (MS) and the diabetic patients,
while HIV patients with the MS had further decrements in FMD. This suggests that
either viremia or HAART negatively affects FMD; traditional risk factors such as the
MS are additive to this risk. The accompanying editorial by Stein addresses the
limitations in the current understanding of HIV and atherosclerosis and provides
insights into upcoming trials. See pages 1117 and 1124. See figure.
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Atherosclerosis
IVUS Palpography May Identify High-Risk Lesions
There is an unmet need to identify and characterize “high-risk” coronary lesions.The Integrated Biomarker and Imaging Study (IBIS) used quantitative
coronary angiography (QCA), multislice computed tomography (MSCT) angiog-
raphy, and two different intravascular ultrasound (IVUS) methods in an attempt
to identify and characterize these potentially unstable lesions. While neither
MSCT nor QCA could reliably track temporal changes in the coronary lesions,
IVUS strain tracking showed promise. This technique which tracks changes in the
distance between two locations in the wall of the artery with changes in blood
pressure has been termed palpography for its presumptive ability to measure the
stiffness of a lesion. The technique may prove useful as a method for tracking
changes in the risk propensity of coronary lesions in response to different therapies.
See page 1134. See figure.
Atherosclerosis
High Levels of Tissue ACE in Unstable Plaques
Several studies have shown that angiotensin-converting enzyme (ACE) inhibitorsreduce the frequency of cardiac events; this reduction appears to be in addition to
the blood pressure lowering effect. The ACE enzyme is known to be present in the
heart and to be upregulated with inflammation. Angiotensin II, the product of the
reaction catalyzed by ACE, increases oxidative stress and reduces nitric oxide produc-
tion. Ribichini and colleagues used directional coronary atherectomy to extract coro-
nary atherosclerotic plaques from patients with stable and unstable angina. The level
and location of ACE in the tissue was determined by immunostaining. They found a
direct correlation between the extent of the ACE expression and the extent of inflam-
mation in patients with unstable syndromes. This study demonstrates that inflamma-
tion and cell proliferation are closely associated with upregulation of ACE in athero-
sclerotic plaques further supporting a role of the enzyme in the pathophysiology of
plaque rupture. See page 1143.
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Hypertrophic Cardiomyopathy
Reduced Myocardial Strain in HCM
Techniques tomeasuremyocardial strain offer the ability to quantify subtle degreesof myocardial dysfunction even when the overall ejection fraction is normal.
Current techniques such as tissueDoppler are limited by angle dependency and lack of
reproducibility. Serri and colleagues used a recently developed software package that is
able to calculate instantaneous strain along multiples axes from two dimensional
echocardiography images. Using this technique, they compared patients with hyper-
trophic cardiomyopathy (HCM) but normal ejection fraction with healthy controls.
They report that longitudinal, transverse, circumferential, and radial strains were all
reduced in subjectswithHCM.The low interobserver variability andwealth of data on
wall mechanics suggest that this technique will find many applications. See page
1175. See figure.
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Vascular Disease
Obesity Impairs Coronary Vasodilation Independently
While obesity is known to be a strong cardiovascular risk factor, it is unclear if thisrisk relates to associated insulin resistance, changes in pro-inflammatory fac-
tors, or is additive to these changes. Schindler and colleagues studied subjects with
varying body mass indexes (BMIs) using positron emission tomography scanning to
detect coronary vasodilation in response to either cold pressor test (CPT) or dipyri-
damole. At baseline, subjects had similar myocardial blood flows. There was a progres-
sive decrease in vasodilation in response to both CPT and dipyridamole as BMI
increased. While C-reactive protein, insulin resistance, and leptin levels were all
correlatedwith obesity, in amultivariablemodel, obesity was the strongest predictor of
a reduced augmentation of myocardial blood flow. This study demonstrates that
obesity is an independent risk factor for impaired coronary vasodilation. See page
1188. See figure.
